AstraZeneca scores Chinese approval for heart failure therapy Forxiga
AstraZeneca said that Forxiga (dapagliflozin) has secured approval in China for its use in the reduction of the risk of cardiovascular (CV) death and hospitalization for heart failure (hHF) in adults having heart failure (NYHA class II-IV) with reduced ejection fraction (HFrEF). The approval for the sodium-glucose co-transporter 2 inhibitor (SGLT2 inhibitor) from the Chinese […]
AstraZeneca has been granted breakthrough therapy designation (BTD) for Farxiga (dapagliflozin) from the US Food and Drug Administration (FDA) for the treatment of patients with chronic kidney disease (CKD), irrespective of type 2 diabetes (T2D). According to the US Centers for Disease Control and Prevention (CDC), chronic kidney disease is a serious, progressive condition defined […]
Continue reading …
AstraZeneca has secured fast track designation for Farxiga (dapagliflozin) in the US for its use in reducing the risk of hospitalization for heart failure (hHF) or cardiovascular (CV) death in adults after an acute myocardial infarction (MI) or heart attack. The fast track designation for the oral once-daily sodium-glucose co-transporter-2 (SGLT2) inhibitor is based on […]
Continue reading …
Business News Today
- Scanpoint Geomatics wins contract from BiharShariff Smart City
- Arbuthnot Banking sells Tay mortgage portfolio to OneSavings Bank
- Clothing retailer Gap to open $140m Customer Experience Center in Longview
- Kiwi insurer Tower to acquire legacy portfolio of ANZ
- World Insurance Associates acquires Corporate Risk Services in Arkansas
- Roivant Sciences to acquire Silicon Therapeutics to boost drug discovery capabilities
- Kotak Mahindra Bank acquires stake in new fintech company Ferbine
- Infosys to expand Pennsylvania Retirement Services Center of Excellence
- Energean takes full ownership of Israeli subsidiary
- Merck to acquire US biotech company Pandion Therapeutics for $1.8bn